INVA Q1 2023 Earnings — Innoviva, Inc. Revenue & Financial Results | Market Cap Arena

INVAInnoviva, Inc.

$1B

Q1 2023 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$76M-15.2% YoY

Gross Profit

$53M70.0% margin

Operating Income

$21M27.6% margin

Net Income

$35M45.7% margin

EPS (Diluted)

$0.42

QoQ Revenue Growth

+16.1%

Cash Flow

Operating Cash Flow

$26M

Free Cash Flow

$26M

Stock-Based Comp.

$2M

Balance Sheet

Total Assets

$1.1B

Total Liabilities

$568M

Stockholders' Equity

$561M

Cash & Equivalents

$144M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$76M	$90M	-15.2%
Gross Profit	$53M	$90M	-40.7%
Operating Income	$21M	$78M	-72.8%
Net Income	$35M	$16M	+121.0%

Revenue Segments

Royalty

$57M73%

Product

$12M15%

License Revenue

$8M10%

License

$2M2%